Search
NOP-1A
go.drugbank.com/drugs/DB15208InvestigationalNOP-1A is under investigation in clinical trial NCT01198197 (PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A).
RD13-02
go.drugbank.com/drugs/DB27110InvestigationalRD13-02 is under investigation in clinical trial NCT05923541 (RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies).
AMP-201
go.drugbank.com/drugs/DB18663ExperimentalIt is under investigation for the treatment of collagen Q congenital myasthenia.
VPM4001
go.drugbank.com/drugs/DB05089ExperimentalVPM4001 is an allogeneic vaccine for treatment of prostate carcinoma.
Elesclomol
go.drugbank.com/drugs/DB05719InvestigationalIt is being developed by Synta Pharmaceuticals. … Elesclomol is a novel, injectable, drug candidate that kills cancer cells by elevating oxidative stress levels beyond a breaking point, triggering programmed cell death.
Endoplasmic reticulum membrane sensor NFE2L1
go.drugbank.com/bio_entities/BE0004168TargetHumansIn response to stress, it is released from the endoplasmic reticulum membrane following cleavage by the protease DDI2 and translocates into the nucleus to form the transcription factor NRF1 (By similarity … Involved in proteasome homeostasis: in response to proteasome inhibition, it is released from the endoplasmic reticulum membrane, translocates to the nucleus and activates expression of genes encoding
Synonyms: Protein NRF1, p120 formTrimethyldiphenylpropylamine
go.drugbank.com/drugs/DB13361ExperimentalCategories: Drugs for Functional Gastrointestinal DisordersPhelimin
go.drugbank.com/drugs/DB18332Experimental[L48151] It is under investigation for the treatment of hyperphenylalaninemia.